Copy to clipboard 
Following FDA premarket approval of the KeriMedical TOUCH CMC 1 Prosthesis, Medartis has decided to acquire the remaining 53% of the privately-held company in accordance with the existing agreement. The transaction values the remaining shares at CHF 99 million in cash (~USD $123 million), with potential additional earn-out payments. Closing is slated for August 2025, and limited U.S. launch of the TOUCH thumb implant is expected in early 2026.
The partnership, which began in December 2020, provides Medartis access to an innovative hand portfolio while enhancing the company’s technological expertise in joint replacement and expanding its surgeon network. Medartis has steadily increased its ownership and now acquires full ownership of the Geneva-headquartered company with its two production facilities in France.
The Medartis Group acts as distribution partner for KeriMedical in Germany, Austria, the UK and most recently Australia, and has doubled its revenue every year during this period. Globally, KeriMedical has delivered average annual growth of nearly 30% over the past three years, achieving total sales of CHF 31 million in 2024. The transaction will immediately contribute positively to Medartis’ sales growth and core EBITDA margin.
KeriMedical will continue operating as a distinct brand within the Medartis Group, maintaining dedicated teams for development, marketing, surgeon education and manufacturing.
“This acquisition is a logical step in our five-year partnership, expanding our capabilities in our core hand & wrist indication. KeriMedical’s distinctive products have contributed to our strong performance in Germany, Austria and the United Kingdom, where we hold the exclusive distribution rights. They are the perfect addition to our comprehensive hand portfolio,” stated Matthias Schupp, CEO of Medartis.
Dougal Bendjaballah and Bernard Prandi, co-founders of KeriMedical, commented: “We are pleased to reach this agreement with Medartis. Since founding the company, we have focused on creating innovative solutions for hand surgery based on scientific excellence and close collaboration with surgeons. In Medartis, we have found a partner whose approach to innovation, quality and medical education aligns perfectly with our vision. Our products still have plenty of potential in Europe, and entering the US and Australian markets will keep us on a strong growth path.”
Source: Medartis
Following FDA premarket approval of the KeriMedical TOUCH CMC 1 Prosthesis, Medartis has decided to acquire the remaining 53% of the privately-held company in accordance with the existing agreement. The transaction values the remaining shares at CHF 99 million in cash (~USD $123 million), with potential additional earn-out payments....
Following FDA premarket approval of the KeriMedical TOUCH CMC 1 Prosthesis, Medartis has decided to acquire the remaining 53% of the privately-held company in accordance with the existing agreement. The transaction values the remaining shares at CHF 99 million in cash (~USD $123 million), with potential additional earn-out payments. Closing is slated for August 2025, and limited U.S. launch of the TOUCH thumb implant is expected in early 2026.
The partnership, which began in December 2020, provides Medartis access to an innovative hand portfolio while enhancing the company’s technological expertise in joint replacement and expanding its surgeon network. Medartis has steadily increased its ownership and now acquires full ownership of the Geneva-headquartered company with its two production facilities in France.
The Medartis Group acts as distribution partner for KeriMedical in Germany, Austria, the UK and most recently Australia, and has doubled its revenue every year during this period. Globally, KeriMedical has delivered average annual growth of nearly 30% over the past three years, achieving total sales of CHF 31 million in 2024. The transaction will immediately contribute positively to Medartis’ sales growth and core EBITDA margin.
KeriMedical will continue operating as a distinct brand within the Medartis Group, maintaining dedicated teams for development, marketing, surgeon education and manufacturing.
“This acquisition is a logical step in our five-year partnership, expanding our capabilities in our core hand & wrist indication. KeriMedical’s distinctive products have contributed to our strong performance in Germany, Austria and the United Kingdom, where we hold the exclusive distribution rights. They are the perfect addition to our comprehensive hand portfolio,” stated Matthias Schupp, CEO of Medartis.
Dougal Bendjaballah and Bernard Prandi, co-founders of KeriMedical, commented: “We are pleased to reach this agreement with Medartis. Since founding the company, we have focused on creating innovative solutions for hand surgery based on scientific excellence and close collaboration with surgeons. In Medartis, we have found a partner whose approach to innovation, quality and medical education aligns perfectly with our vision. Our products still have plenty of potential in Europe, and entering the US and Australian markets will keep us on a strong growth path.”
Source: Medartis
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
